INTRODUCTION AND OBJECTIVES: mpMRI offers the possibility to locate cancer in 3-Dimensions and aid surgical planning. We investigated the margin needed around an mpMRI lesion for complete disease control in a prospectively enrolled biopsy naïve population who underwent mpMRI followed by Transperineal Prostate Mapping with biopsies taken every 5mm(5TPM).
INTRODUCTION AND OBJECTIVES: mpMRI offers the possibility to locate cancer in 3-Dimensions and aid surgical planning. We investigated the margin needed around an mpMRI lesion for complete disease control in a prospectively enrolled biopsy naïve population who underwent mpMRI followed by Transperineal Prostate Mapping with biopsies taken every 5mm(5TPM).
METHODS: 94 patients included in this analysis were part of the pilot phase of Prostate MRI Imaging Study (NCT01292291) investigating accuracy of mpMRI against standard of care with TPM as a reference test. All patients were biopsy-naïve with a PSA below 15ng/ ml. All patients underwent 1.5T mpMRI with standardized protocol (T2W, Diffusion, DCE), blinded reported using Likert scoring. Each core was separately labelled and oriented in space. Each prostate and MRI lesion was contoured on T2W-imaging, blinded to pathology. A 3D digital map of the TPM was reconstructed using an in-house software. Correlation between mpMRI and biopsy findings was automatically carried out using a platform generating the registration based on landmarks. We report the margin 'M' around the MRI lesion as the maximum distance within a set of negative biopsy location surrounding the MRI lesion. Results are also stratified by MRI score, Gleason Score, lesion eligibility to focal therapy and significance.
RESULTS: 41 patients (median PSA 6.5ng/ml, median age 62) were found to harbour cancer at 5TPM in this cohort, yielding 75 MRI lesions that corresponded to cancer at 5TPM. The median number of MRI lesions per patient was 1.5. As a control of registration, correlation between MRI volume and TPM volume was ?¼0.92 (p<0.001). Lesion characteristics are summarized in Table 1 . The mean margin (enclosing a perimeter of negative cores) for MRI lesions corresponding the cancer at 5TPM was 7.0 mm (SD 4.6mm). For lesion eligible for focal therapy (n¼ 35), the mean margin was 7.3 (SD 4.3mm). The mean Gleason score of biopsy core outside the MRI lesion was 6.7 (+/-0.5).
CONCLUSIONS: Our study is the first to report a margin around a mpMRI lesion when based on prostates that have not been removed using surgery and evaluated against a very accurate 3-dimensional 5mm mapping biopsy. These findings have implications for focal therapy and nerve-sparing surgery. MRI) is the most common imaging modality used for detecting residual cancer following Partial Gland Ablation (PGA) for Prostate Cancer. The aim of this study was to assess the diagnostic accuracy of mp-MRI to detect residual cancer in the ablated area following PGA and to assess whether a biopsy of the ablated area may be avoided based on MRI.
Source of
METHODS: Prospectively maintained institutional database was queried to identify 65 patients with primary PGA from May 2010 to February 2016 and had a postoperative MRI and a control biopsy within 18 months after the procedure. All the MRIs were reviewed by a single radiologist blinded to the biopsy results and visible abnormalities in the ablated area were scored based on a 5-point Likert scale and PIRADS V2. Univariate generalized estimating equation regression with an exchangeable correlation structure to account for within patient correlation was used to test the association between a high MRI score (Likert or PIRADS score ¼3) and any-(Gleason ¼6) and high-grade (Gleason ¼7) disease detected on biopsy of the ablated area.
RESULTS: After exclusions, we identified 38 post-PGA MRI and biopsy pairs with 6 patients having 2 MRI/biopsy combinations. Any-grade disease was detected on 15 biopsies (39%; 95% CI 24%, 57%) and high-grade on 2 biopsies (5.3%; 95% CI 0.6%, 18%). Patient with MRI lesion of Likert and PIRADS score ¼3 in the ablated area were 8 (21%) and 7 (18%) respectively. Both the 2 instances of high-grade disease detected on biopsy occurred among the 8 MRIs with a Likert score ¼3 (25%; 95% CI 3.2%, 65%) and 7 MRIs with a PIRADS score ¼3. No high-grade disease was detected among participants with a Likert or PIRADS score <3, the upper bound of a 97.5% exact confidence interval was 11.6% and 11.2% based on Likert score (n¼30) and PIRADS Score (n¼31) respectively. One patient had a PIRADS score of 5 and had a Gleason 6 disease detected on biopsy. We did not find sufficient evidence to suggest an association between a PIRADS score and any-grade disease (p ¼ 0.6) nor between Likert score and anygrade disease (p ¼ 0.9), the association was not estimable as we had no participants with high-grade disease with an MRI score less than 3.
CONCLUSIONS: This preliminary study was unable to identify an association between MRI scores and presence of prostate cancer in the treated area following PGA therapy. Men with MRI scores of <3 should not be precluded from biopsy given that it is plausible that the rate of high-grade disease is meaningfully high.
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